Biotie will publish its Financial Statement Release for 1

BIOTIE THERAPIES CORP.     STOCK EXCHANGE ANNOUNCEMENT 23 February 2010 at 4.30
p.m.
Biotie will publish its Financial Statement Release for 1 January ‑ 31 December
2009 on Friday, 26 February 2010 at 9.00 a.m. Finnish time.

The webcast and conference call will be arranged on the publishing day at 1.00
p.m Finnish time (12.00 noon CET, 11.00 a.m UK time), and will also be available
as live audio webcast at www.biotie.com. The call will be held in English. The
Financial Statement Release will be presented by President and CEO Timo Veromaa.

Callers may access the conference directly at the following telephone numbers:
UK: +44 (0) 203 003 2666, Finland: 0800 914672, no code. Lines are to be
reserved ten minutes before the start of conference call.

An on-demand audiocast of the conference will also be published on Biotie's
website later during the day.

Biotie publishes financial information in English and Finnish. All
releases are posted in full on Biotie's website as soon as they are published.

Turku, February 23, 2010

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Investor Relations Manager
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com
<mailto:virve.nurmi@biotie.com>


Distribution:
NASDAQ OMX Helsinki Ltd
Main Media


Biotie Therapies Corp.
Biotie is a drug discovery and development company focused on central nervous
system and inflammatory diseases. It has a broad range of innovative small
molecule and biological drug candidates at different stages of clinical and
pre-clinical development. Biotie's products address diseases with high unmet
medical need and significant market potential, including addiction and psychotic
disorders, rheumatoid arthritis, psoriasis and chronic obstructive pulmonary
disease (COPD). The most advanced product, nalmefene for alcohol dependence, is
currently in phase III clinical development by licensing partner H. Lundbeck
A/S.

The commercial value of the pipeline has been demonstrated through existing
alliances with top-tier global pharmaceutical companies such as Lundbeck, Roche
and Pfizer. Biotie has operations in Turku, Finland and Radebeul, Germany.

Biotie shares are listed on NASDAQ OMX Helsinki Ltd.

For more information, please refer to www.biotie.com


[HUG#1387519]
Biotie will publish its Financial Statement Release for 1 January ‑ 31 December 2009 on Friday, 26 February 2010 at 9.00 a.m. Finnish time
